{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:43:55Z","timestamp":1784713435824,"version":"3.55.0"},"reference-count":34,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/14760584.2025.2480297","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T08:15:43Z","timestamp":1742285743000},"page":"221-229","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine"],"prefix":"10.1080","volume":"24","author":[{"given":"Martina","family":"Rauscher","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeb","family":"Youard","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Faccin","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay S.","family":"Patel","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Pang","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Zent","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_3_10_3_1","unstructured":"World Health Organisation. Dengue and severe dengue. [2024 Jun 10]. Available from: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue"},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002217"},{"key":"e_1_3_10_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202005"},{"key":"e_1_3_10_6_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-055522"},{"key":"e_1_3_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed8020086"},{"key":"e_1_3_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003226"},{"key":"e_1_3_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00088-8"},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/515144"},{"key":"e_1_3_10_11_1","doi-asserted-by":"publisher","DOI":"10.1257\/app.20210656"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(17)30021-4"},{"key":"e_1_3_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac418"},{"key":"e_1_3_10_14_1","unstructured":"Takeda. Takeda\u2019s QDENGA\u00ae (Dengue Tetravalent Vaccine [live attenuated]) approved in Indonesia for use regardless of prior dengue exposure. [cited 2024 Jun 14]. Available from: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2022\/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-dengue-exposure\/"},{"key":"e_1_3_10_15_1","unstructured":"Takeda. Vacina QDENGA\u00ae (vacina dengue 1 2 3 e 4 [atenuada]) da Takeda \u00e9 aprovada no Brasil para uso independentemente de exposi\u00e7\u00e3o pr\u00e9via \u00e0 dengue. [cited 2024 Jun 14]. Available from: https:\/\/www.takeda.com\/pt-br\/Newsroom\/releases\/2023\/vacina-qdenga-vacina-dengue-1-2-3-e-4-atenuada-da-takeda-e-aprovada-no-brasil-para-uso-independentemente-de-exposicao-previa-a-dengue"},{"key":"e_1_3_10_16_1","unstructured":"Takeda. Takeda\u2019s QDENGA\u00ae (Dengue Tetravalent Vaccine [live attenuated]) approved for use in European Union. [cited 2024 Jun 14]. Available from: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2022\/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-for-use-in-european-union\/"},{"key":"e_1_3_10_17_1","unstructured":"European Medicines Agency. Qdenga: dengue tetravalent vaccine (live attenuated). [cited 2024 Jun 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qdenga"},{"key":"e_1_3_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903869"},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780195387902.003.0032"},{"key":"e_1_3_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.045"},{"key":"e_1_3_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)82056-6"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1966.tb01796.x"},{"key":"e_1_3_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1966.tb01796.x"},{"key":"e_1_3_10_24_1","volume-title":"American Society of Tropical Medicine and Hygiene Annual Meeting; 2023 18\u201322 October","author":"El HIndi T","unstructured":"El HIndi T, Anugulruengkitt S, Lapphra K, et al. Immunogenicity and safety following coadministration of a live, attenuated tetravalent dengue vaccine and a recombinant 9-valent human papillomavirus vaccine in healthy participants aged \u22659 to <15 years in a dengue endemic country (LB-8565). American Society of Tropical Medicine and Hygiene Annual Meeting; 2023 18\u201322 October; Chicago, IL, USA."},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2023.102624"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13783"},{"key":"e_1_3_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3676"},{"key":"e_1_3_10_28_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-72032010000300002"},{"key":"e_1_3_10_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7251.1708"},{"key":"e_1_3_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198807283190401"},{"key":"e_1_3_10_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l869"},{"key":"e_1_3_10_32_1","first-page":"541","volume-title":"Uropathology","author":"Zhou M","year":"2023","unstructured":"Zhou M, Netto GJ, Epstein JI. Chapter 244 - Hydrocele. In: Uropathology. 2nd ed. Philadelphia (PA): Elsevier; 2023. p. 541\u2013542. https:\/\/www.sciencedirect.com\/book\/9780323653954\/uropathology","edition":"2"},{"key":"e_1_3_10_33_1","unstructured":"Takeda. Summary of product characteristics QDENGA\u00ae dengue tetravalent vaccine (live attenuated). [cited 2024 Jun 14]. Available from: https:\/\/assets-dam.takeda.com\/raw\/upload\/v1674594191\/legacy-dotcom\/siteassets\/system\/what-we-do\/areas-of-focus\/vaccines\/pdf\/ACC_Qdenga_SmPC.pdf"},{"key":"e_1_3_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.050"},{"key":"e_1_3_10_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010124"},{"key":"e_1_3_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.052"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2025.2480297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:38:00Z","timestamp":1765521480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2025.2480297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/14760584.2025.2480297"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2025.2480297","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}